Tim Malcolm
AstraZeneca (United Kingdom)(GB)University of Cambridge(GB)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Immune Cell Function and Interaction, CAR-T cell therapy research, Cytokine Signaling Pathways and Interactions, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → STAT3 regulated ARF expression suppresses prostate cancer metastasis(2015)179 cited
- → Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress(2016)83 cited
- → STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway(2023)54 cited
- → Challenging perspectives on the cellular origins of lymphoma(2016)51 cited
- → Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin(2014)46 cited
- → A simeprevir-inducible molecular switch for the control of cell and gene therapies(2023)10 cited
- → Paediatric Burkitt lymphoma patient‐derived xenografts capture disease characteristics over time and are a model for therapy(2020)6 cited
- → Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis(2015)6 cited
- → The demon drink(1992)1 cited
- → Abstract 671: Assessing the origins of anaplastic large cell lymphoma in murine models via forced lineage specificity of NPM-ALK expression in T cells(2016)